Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03241537 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

COHORT Trial in Clinical Pelivc Lymph Node Metastatic Prostate Cancer

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 31, 2022 to Dec 14, 2026v7
  2. Phase: Not applicable to Phase 3v6 Show 5 more changesShow less
    • Primary completion date: Dec 31, 2021 to Dec 31, 2022
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 30 to confirmed 61
    • Study completion date: Mar 14, 2026 to Dec 14, 2026
    • Site details revised
  3. Primary completion date: Mar 14, 2021 to Dec 31, 2021v5
  4. Enrollment target: 246 to 30v4 Show 4 more changesShow less
    • Primary completion date: Jan 14, 2019 to Mar 14, 2021
    • Primary endpoint revised
    • Study completion date: Jan 14, 2026 to Mar 14, 2026
    • Secondary endpoints revised (5)
  5. 2 versions Re-verified since Sep 6, 2018, no change to tracked fieldsv2-v3
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In local advanced prostate cancer patients with clinically positive metastatic regional lymph node, the optimal treatment is still unanswered. For these patients, radiotherapy combined with hormonal therapy or hormonal therapy alone are recommended. Recently, the reports from NCCB and SEER data showed that radiotherapy combined with hormonal therapy have better survivals than hormonal therapy alone. This randomized phase III trial compare hormonal therapy alone with combined hormone with radiotherapy in clinically pelvic lymph node metastatic prostate cancer.
Trial Details
NCT Number NCT03241537
Lead Sponsor Samsung Medical Center
Conditions
(from sponsor)		 Prostate Neoplasm
Related terms Prostatic Neoplasms
Enrollment 61 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov